A mouse model for studying viscerotropic disease caused by yellow fever virus infection.
Mosquito-borne yellow fever virus (YFV) causes highly lethal, viscerotropic disease in humans and non-human primates. Despite the availability of efficacious live-attenuated vaccine strains, 17D-204 and 17DD, derived by serial passage of pathogenic YFV strain Asibi, YFV continues to pose a significant threat to human health. Neither the disease caused by wild-type YFV, nor the molecular determinants of vaccine attenuation and immunogenicity, have been well characterized, in large part due to the lack of a small animal model for viscerotropic YFV infection. Here, we describe a small animal model for wild-type YFV that manifests clinical disease representative of that seen in primates without adaptation of the virus to the host, which was required for the current hamster YF model. Investigation of the role of type I interferon (IFN-alpha/beta) in protection of mice from viscerotropic YFV infection revealed that mice deficient in the IFN-alpha/beta receptor (A129) or the STAT1 signaling molecule (STAT129) were highly susceptible to infection and disease, succumbing within 6-7 days. Importantly, these animals developed viscerotropic disease reminiscent of human YF, instead of the encephalitic signs typically observed in mice. Rapid viremic dissemination and extensive replication in visceral organs, spleen and liver, was associated with severe pathologies in these tissues and dramatically elevated MCP-1 and IL-6 levels, suggestive of a cytokine storm. In striking contrast, infection of A129 and STAT129 mice with the 17D-204 vaccine virus was subclinical, similar to immunization in humans. Although, like wild-type YFV, 17D-204 virus amplified within regional lymph nodes and seeded a serum viremia in A129 mice, infection of visceral organs was rarely established and rapidly cleared, possibly by type II IFN-dependent mechanisms. The ability to establish systemic infection and cause viscerotropic disease in A129 mice correlated with infectivity for A129-derived, but not WT129-derived, macrophages and dendritic cells in vitro, suggesting a role for these cells in YFV pathogenesis. We conclude that the ability of wild-type YFV to evade and/or disable components of the IFN-alpha/beta response may be primate-specific such that infection of mice with a functional IFN-alpha/beta antiviral response is attenuated. Consequently, subcutaneous YFV infection of A129 mice represents a biologically relevant model for studying viscerotropic infection and disease development following wild-type virus inoculation, as well as mechanisms of 17D-204 vaccine attenuation, without a requirement for adaptation of the virus.
Meier
Kathryn C
KC
Department of Microbiology & Immunology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America.
Gardner
Christina L
CL
Khoretonenko
Mikhail V
MV
Klimstra
William B
WB
Ryman
Kate D
KD
D000818:Animals; D001854:Bone Marrow Cells / Q000821:virology; D006224:Cricetinae; D009033:Culicidae / Q000821:virology; D003713:Dendritic Cells / Q000821:virology; D004195:Disease Models, Animal; D020022:Genetic Predisposition to Disease; D022781:Hepatocytes / Q000821:virology; D008264:Macrophages / Q000821:virology; D051379:Mice; D018345:Mice, Knockout; D011323:Primates / Q000382:microbiology; D053633:Receptor, Interferon alpha-beta / Q000235:genetics; D017471:Receptors, Interferon / Q000172:deficiency / Q000235:genetics; D015398:Signal Transduction; D015004:Yellow Fever / Q000235:genetics / Q000276:immunology / Q000503:physiopathology*; D022341:Yellow Fever Vaccine; D015005:Yellow fever virus / Q000472:pathogenicity*; D000096743:Interferon gamma Receptor
D053633:Receptor, Interferon alpha-beta; D017471:Receptors, Interferon; D022341:Yellow Fever Vaccine; D000096743:Interferon gamma Receptor